Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy - The Guardian

Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy  The GuardianVeracyte genomic test identifies breast cancer patients who can skip chemo  ReutersGenetic test could offer breast cancer patients chance to skip chemo  The TimesLandmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy  Business WireOPTIMA Phase III: Gene Expression Test Helps Identify Patients Who May Avoid Chemotherapy  Docwire News